General Ophthalmology - Eye Health Academy

1-16 of 52

Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR
Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR
Ophthalmology
Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR
Jordan Deaner; Vaidehi S. Dedania, MD
- Jordan Deaner
- Vaidehi S. Dedania, MD
- Rehan M. Hussain, MD
Trends in PDR Treatments
Trends in PDR Treatments
Ophthalmology
Trends in PDR Treatments
Maria H. Berrocal, MD; Katharine Talcott, MD
- Maria H. Berrocal, MD
- Katharine Talcott, MD
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
Eye on Ocular Health
Logistical Considerations with Anti-VEGF Treatment in Wet AMD
GLP-1 Use and AMD Risk
GLP-1 Use and AMD Risk
Ophthalmology
GLP-1 Use and AMD Risk
Barton Lynn Blackorby, MD; Katharine Talcott, MD
- Barton Lynn Blackorby, MD
- Katharine Talcott, MD
- Hong-Uyen Hua, MD
MH Risk Factors After RRD Repair
MH Risk Factors After RRD Repair
Ophthalmology
MH Risk Factors After RRD Repair
Maria H. Berrocal, MD; Avni P. Finn, MD, MBA
- Maria H. Berrocal, MD
- Avni P. Finn, MD, MBA
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Eye on Ocular Health
Time to Recurrence and Early Risk Indicators in BRVO-Related Macular Edema
Outcomes for PDR Patients LTFU for at Least 1 Year
Outcomes for PDR Patients LTFU for at Least 1 Year
Ophthalmology
Outcomes for PDR Patients LTFU for at Least 1 Year
Kyle Davis Kovacs, MD; Matt Starr, MD
- Kyle Davis Kovacs, MD
- Matt Starr, MD
- Nita Valikodath, MD, MS
Examining Therapeutic Timing in RVO-Related Macular Edema
Examining Therapeutic Timing in RVO-Related Macular Edema
Eye on Ocular Health
Examining Therapeutic Timing in RVO-Related Macular Edema
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Ophthalmology
Real-World Switching to Faricimab from Legacy Anti-VEGFs in Wet AMD
Maria H. Berrocal, MD; Lejla Vajzovic, MD, FASRS
- Maria H. Berrocal, MD
- Lejla Vajzovic, MD, FASRS
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Eye on Ocular Health
How Anti-VEGF Compares with Steroids in Retinal Vein Occlusion
Ryan Quigley
- Ryan Quigley
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Ophthalmology
Suprachoroidal Steroids in Patients With a History of Glaucoma and Ocular Hypertension
Maria H. Berrocal, MD; Danny Mammo, MD
- Maria H. Berrocal, MD
- Danny Mammo, MD
Diagnosis Delays in Stargardt Disease
Diagnosis Delays in Stargardt Disease
Ophthalmology
Diagnosis Delays in Stargardt Disease
Alexis Warren, MD; Jesse Sengillo, MD
- Alexis Warren, MD
- Jesse Sengillo, MD
- Sruthi Arepalli, MD
Redefining The Cash-Pay Model in Modern Optometric Practice
Redefining The Cash-Pay Model in Modern Optometric Practice
Modern Optometry
Redefining The Cash-Pay Model in Modern Optometric Practice
Jason E. Compton, OD, FAAO
- Jason E. Compton, OD, FAAO
Elevating Clinical Efficiency
Elevating Clinical Efficiency
Modern Optometry
Elevating Clinical Efficiency
Diana Chu
- Diana Chu
Practice Efficiency and Innovation
Practice Efficiency and Innovation
Modern Optometry
Practice Efficiency and Innovation
Jacob Lang
- Jacob Lang
Tailored Treatment in Retinal Disease: Using Biomarkers to Guide Anti-VEGF Therapy
Tailored Treatment in Retinal Disease: Using Biomarkers to Guide Anti-VEGF Therapy
Eye on Ocular Health
Tailored Treatment in Retinal Disease: Using Biomarkers to Guide Anti-VEGF Therapy
Jennifer Caudle, DO, FACOFP; Michael Javaheri, MD, MSc, FASRS
- Jennifer Caudle, DO, FACOFP
- Michael Javaheri, MD, MSc, FASRS

Prev
1
2
3
4
Next

1/4